Novartis
NEWS
So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
Shares of Aveo are falling this morning after the company revealed Novartis has walked away from its development deal for the company’s proprietary antibody AV-380, as well as other antibodies that inhibit Growth Differentiation Factor 15.
Biotech manufacturing is the non-glamorous side of biopharma, although its impact on the economy shouldn’t be underestimated. Here’s everything you need to know.
Adamis Pharmaceuticals is selling U.S. commercial rights to Symjepi, a competitor to Mylan’s EpiPen, to Novartis.
Switzerland-based Novartis announced it plans to spin off Alcon, its eye care division, into a separately-traded standalone company.
Eli Lilly and Company announced the results of its COAST-W Phase III clinical trial of Taltz (ixekizumab) to treat Ankylosing Spondylitis (AS). The trial met both primary and major secondary endpoints.
It feels like we’re standing on the edge of a precipice. Despite the ho-hum recent performance of biotech stocks, amazing things are about to happen. And one of the most amazing of all is gene therapy.
The Dementia Discovery Fund (DDF), a venture capital fund focused solely on dementia-related investments, completed $350 million of fundraising. The initial target was $200 million.
An experimental triple combination treatment for cystic fibrosis has landed Vertex Pharmaceuticals at the top of EvaluatePharma’s “World Preview 2018” list.
JOBS
IN THE PRESS